Page URL:

European approval for skin cancer drug that could double lifespan

27 February 2012
Appeared in BioNews 646

The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span.

The drug, which works by targeting a genetic mutation present in the tumours of approximately half of all melanoma patients, comes with its own diagnostic genetic test in order to identify which patients could benefit.

Vemurafenib (Zelboraf) was developed by Roche and according to Hal Barron, chief medical officer and head of product development at the company it 'exemplifies the benefits that [a] personalised approach to medicine can provide for patients, physicians and society'.

Dr Antoni Ribas, a professor of haematology and oncology at the Jonsson Cancer Center at the University of California, Los Angeles, who led the most recent drug trial, agrees. He says the results 'tell us that this drug is having a very big impact, and this changes the way we treat metastatic melanoma'.

Vemurafenib works by switching off the activity of a gene called BRAF, which is normally involved in regulating when a cell divides. When BRAF is mutated, as in some metastatic melanomas, it becomes permanently switched on, leading to excessive cell division and the formation of a tumour.

The trial run by Dr Ribas looked at 132 patients whose tumours all contained this BRAF mutation. The results, published in The New England Journal of Medicine, showed that vemurafenib treatment, while not curing the cancer, shrunk the melanomas 'better than chemotherapy' and extended the median lifespan of patients to 16 months, compared with nine months when using conventional treatment.

This is the first new drug developed for this disease in over a decade, which Roche is taking as a sign that their approach of designing personalised medicines along with diagnostic tests to identify suitable patients is the way forward. But while the drug is promising, there are some concerns.

In the latest trial only 53 percent of patients responded to the drug, despite all carrying the mutation, which has important implications when calculating costs. If this is the case in the general population, this would mean that only around 25 percent of metastatic melanoma patients would benefit. However, according to the authors, this still compares quite favourably to the typical response rate of less than 10 percent for the few alternative treatment options currently available.

In addition, the cancer will eventually become resistant to the drug, and start to grow again. This is currently the major limiting factor associated with many of the cancer drugs targeted at specific mutations.

'We're getting somewhere with these targeted drugs but we have a whole raft of research still to do to address the issue of resistance', says Kate Law, director of clinical and population research at Cancer Research UK.

Melanoma drug nearly doubles survival time: study
Time |  24 February 2012
New drug can double melanoma survival
The Australian |  23 February 2012
Roche's New Skin Cancer Drug Zelboraf Gets European Approval
Fox Business |  23 February 2012
Skin cancer drug hopes raised by study
BBC |  23 February 2012
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
New England Journal of Medicine |  23 February 2012
24 August 2015 - by Kirsty Oswald 
Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...
22 September 2014 - by Dr Lanay Griessner 
A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...
5 November 2012 - by Maria Sheppard 
A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...
28 May 2012 - by James Brooks 
A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris...
15 May 2012 - by Dr Louisa Petchey 
Whole genome sequencing of melanoma, the deadliest form of skin cancer, has confirmed the long held belief that greater sun exposure raises cancer risk by increasing the frequency of genetic mutation. The study also identifies one gene, PREX2, that is mutated in 14 percent of cases...
28 November 2011 - by Dr Rosie Morley 
An initiative has been launched to collect genetic data from NHS cancer patients in the hope of developing new, personalised treatments....
14 November 2011 - by Dr Louisa Petchey 
A new genetic test that will help to tailor drugs to cancer patients' individual tumours has been successfully trialled in the US...
22 August 2011 - by Dr Rosie Morley 
A new study has found that caffeine could help to block cancer formation in UV-sensitive mice by increasing the likelihood of damaged cells dying after sun exposure. The findings suggest caffeine could help protect against skin cancer by promoting the death of cells with damaged DNA....
27 April 2009 - by Lorna Stewart 
Having dark hair and tanning easily does not necessarily make you less likely to develop skin cancer, according to data presented last week at the annual meeting for the American Association for Cancer Research in Denver. Researchers from the University of Pennsylvania, US, found that people who...
30 March 2009 - by Dr Rebecca Robey 
US scientists have found a link between a variant in the gene MDM2, called MDM2 SNP309, and the occurrence of melanoma in younger women. The study, published in the journal Clinical Cancer Research, found that MDM2 SNP309 was significantly more common in women who were diagnosed with...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.